NCT03887650View on ClinicalTrials.gov

LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

January 11, 2022

Study Completion Date

March 8, 2022

Conditions
Post-operative PainTotal Shoulder ArthroplastyOsteoarthritis of the ShoulderPain Management
Interventions
DRUG

Liposomal Bupivicaine 1.3%

10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block

DRUG

Bupivacaine 0.5%

20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block

Trial Locations (1)

06102

The Bone and Joint Institute at Hartford Hospital, Hartford

All Listed Sponsors
lead

Hartford Hospital

OTHER

NCT03887650 - LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs | Biotech Hunter | Biotech Hunter